UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 112, 2020

Aradigm Corporation

(Exact name of registrant as specified in its charter)

California	001-36480	94-3133088
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
39655 Eureka Drive, Newark, California		94560
(Address of principal executive offices)		(Zip Code)


39655 Eureka Drive, Newark, California		94560
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (510) 265-9000

3929 Point Eden Way, Hayward, California

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	ARDMQ	OTC Pink

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

AsOn ~~described in the Form~~June ~~8-K filed by Aradigm Corporation (the “Company”) on April 30~~12, 2020, the Bankruptcy Court entered an order ~~(i) conditionally~~confirming ~~approving~~ the ~~disclosure~~Debtor’s ~~statement~~Modified ~~for the~~ Combined Chapter 11 Plan and Disclosure Statement (the “~~Combined~~ Plan”) filed by Aradigm Corporation (the “Company”);. ~~(ii) directing~~The Effective Date (the ~~Company~~“Effective toDate ~~distribute~~”) of the ~~Combined~~ Plan towill ~~creditors~~be ~~and~~June 29, ~~shareholders~~2020. ~~for~~The ~~voting;~~Company will be dissolved and ~~(iii) fixing~~its ~~April 24,~~stock ~~2020~~cancelled as of the ~~record~~Effective ~~date~~Date ~~for~~after ~~shareholders~~market close and ~~creditors~~the Company’s assets will be contributed to ~~vote~~a Liquidating Trust.

As described in the Forms ~~8-K~~8K filed by the Company on April 3, 2020 and on April 13, 2020, the Company sold its assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof to Grifols S.A. for cash, the right to receive milestone payments on the occurrence of certain events and the right to receive royalty payments based on future sales of the product. The Combined Plan provides that on the Effective Date of the ~~Combined~~ Plan these assets (less amounts paid for certain expenses), as well as the Company’s other assets, will be contributed to a ~~liquidating~~Liquidating ~~trust~~Trust for the benefit of the Company’s creditors and shareholders. ~~The~~As mentioned above, the Company’s stock will be cancelled as of the Effective Date (June 29) after market close and ~~creditors~~the Company will be dissolved. Creditors and shareholders will receive a pro rata interest in the ~~liquidating~~Liquidating ~~trust~~Trust. The ~~liquidating~~Liquidating ~~trust~~Trust will satisfy the claims of the Company’s priority creditors and will collect any milestone payments and royalty payments that are earned and distribute the proceeds to the Company’s creditors. After creditors are paid in full with interest, the ~~liquidating~~ ~~trust~~Liquidating Trust will distribute any remaining proceeds that are received to the Company’s shareholders.

The ~~deadline~~address ~~for~~of ~~creditors~~the ~~and shareholders~~Liquidating toTrust ~~return~~from ~~their~~and ~~ballots~~after ~~voting~~June 29, on2020 ~~the~~will ~~Combined~~be ~~Plan~~Aradigm ~~was~~Corporation Liquidating ~~June 1~~Trust, ~~2020.~~c/o ~~All~~Susan ~~classes~~L. ofUecker, ~~creditors~~Liquidating ~~and~~Trustee, ~~the~~Uecker & ~~requisite~~Associates, ~~majority~~Inc., of1613 ~~shareholders~~Lyon ~~voted~~Street, toSuite ~~accept~~A, ~~the~~San ~~Combined~~Francisco, ~~Plan~~CA 94115.

The ~~Combined~~ Plan is ~~subject~~on tofile ~~the~~with ~~approval of~~ the Bankruptcy Court. ~~The~~This ~~Bankruptcy~~description ~~Court~~of ~~has scheduled a hearing for June 10, 2020 to consider whether to confirm~~ the Combined Plan asis ~~provided~~qualified in 11its ~~U.S.C.~~entirety ~~§ 1129.~~by ~~Aradigm anticipates that~~ the ~~Bankruptcy~~terms ~~Court is likely to confirm the Combined Plan, that the Effective Date~~ of the ~~Combined~~ Plan ~~will be June 26, 2020, and that the cancellation of the Company’s stock will occur on the Effective Date after market close~~.

~~The~~Item ~~Combined Plan is on file with the Bankruptcy Court~~9. ~~This~~01 ~~description~~Financial ofStatements ~~the~~and ~~Combined Plan is qualified in its entirety by the terms of the Combined Plan~~Exhibits.

~~SIGNATURES~~(d) Exhibits.

~~Pursuant~~99.1 toPress ~~the~~Release ~~requirements~~ of ~~the~~Aradigm ~~Securities~~Corporation ~~Exchange~~dated ~~Act~~June ~~of 1934~~15, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~ 2020

	ARADIGM CORPORATION
Dated: June 4, 2020	By:	/s/ John M. Siebert
		Name: John M. Siebert
		Title: Acting Principal Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARADIGM CORPORATION

Dated: June 15, 2020

/s/ John M. Siebert

Name: John M. Siebert

Title: Acting Principal Executive Officer

Filing Compare · ARADIGM CORP